NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the Barclays Capital Global Healthcare Conference in Miami, Florida on Wednesday, March 13, 2013 at 11:15 a.m. ET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may access the webcast from the investors’ calendar of events page on the NPS website at http://www.npsp.com/calendar.
About NPS Pharmaceuticals
NPS Pharmaceuticals is a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The company’s lead product, Gattex® 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection is FDA-approved for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. NPS is also developing Natpara® (rhPTH[1-84]) for the treatment of adult hypoparathyroidism and expects to submit its Biologic License Application (BLA) to the FDA in 2013. NPS's earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, Kyowa Hakko Kirin, and Takeda GmbH.
NPS Pharmaceuticals, Inc.
Gail Brophy, 908-450-5335
.is(':checked'))MM_swapImgRestore(); else MM_swapImage('Checkbox1','','http://im.mstar.com/Im/Mbr/Form_PremCheckbox_Checked.gif',1);void($('#emailMe').attr('checked', !$('#emailMe').is(':checked')))){kind=small}
News More...
| NPS Pharmaceuticals Inc | View npsp Stock Quote | |||
| NPS Pharmaceuticals Inc | View npsp Stock Quote | |||
| Start Premium Trial | Register For Free |
| P | F | Fund Financial Data (13,000+ funds) |
| P | F | Stock Financial Data (7,000+ stocks) |
| P | F | Stock and Fund Screeners (basic) |
| P | F | Investing Articles and Market Commentary |
| P | F | Articles Archive (>30 days) |
| P | F | Discuss (dozens of stock, fund, bond, and general bulletin boards) |
| P | F | Portfolio Manager (basic) |
| P | F | Morningstar Investment Classroom |
| P | F | Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise) |
| P | Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs) | |
| P | Morningstar Stock Analyst Reports (full research on 2,000 stocks) | |
| P | Morningstar Stock and Fund Stewardship Grades | |
| P | Portfolio Manager (advanced with 10 x-ray analyses, including guidance) | |
| P | Portfolio Monitor (monthly and on-demand personalized portfolio statements) | |
| P | Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more) | |
| P | Morningstar Stock and Fund Favorites & Red Flags eNewsletters | |
| P | Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you) | |
| P | Discounts on Morningstar newsletters, books, seminars, and more |